Piper Sandler Cuts Gamida Cell (NASDAQ:GMDA) Price Target to $2.00

Gamida Cell (NASDAQ:GMDA – Free Report) had its price objective trimmed by Piper Sandler from $5.00 to $2.00 in a research report sent to investors on Wednesday morning, Benzinga reports. The firm currently has an overweight rating on the stock. Other equities analysts have also recently issued research reports about the stock. HC Wainwright lowered […]

Leave a Reply

Your email address will not be published.

Previous post HC Wainwright Raises Legend Biotech (NASDAQ:LEGN) Price Target to $87.00
Next post Icosavax (NASDAQ:ICVX) Stock Rating Reaffirmed by William Blair